Journal of Biomedical and Pharmaceutical Research
Available Online at www.jbpr.in
CODEN: - JBPRAU (Source: - American Chemical Society)
NLM (National Library of Medicine): ID: (101671502)
Index Copernicus Value 2022: 83.058
Volume 13, Issue 5; 2024, 1-16

ISSN (Online): 2279-0594
ISSN (Print): 2589-8752

Review Article

Molecular Farming: Biotechnological Approaches for Producing High-Value Plant-derived Pharmaceuticals

Dr Rashmi Jachak

Associate Professor in Botany, Seth Ksarimal Porwal College of Arts & Science & Commerce, Kamptee.

Article Info: Received: 11-07-2024 / Revised: 27-07-2024 / Accepted: 18-08-2024
Address for correspondence: Dr Rashmi Jachak
DOI: https://doi.org/10.32553/jbpr.v13i5.1121
Conflict of interest statement: No conflict of interest

Abstract

Molecular farming is an advanced biotechnological breakthrough that utilises transgenic plants to behave as biofactories, manufacturing intricate and valuable medicinal proteins. This discipline combines modern genetic engineering techniques with conventional agricultural practices to facilitate the sustainable manufacturing of biopharmaceuticals, such as vaccines, monoclonal antibodies, and medicinal enzymes. Molecular farming enables the precise expression of therapeutic proteins by incorporating transgenes encoding these proteins into plant genomes. This process takes place in a regulated and biosafe environment, resulting in a cost-effective production system. This study explores advanced biotechnology methods that are now leading the field of molecular farming. The text emphasizes the utilization of cutting-edge gene-editing techniques, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) and Transcription Activator-Like Effector Nucleases (TALENs). These methods not only enable accurate genomic insertions but also improve the efficiency of gene expression at the transcriptional and translational levels in plant cells. The use of both conventional viral vectors and novel synthetic vector systems is crucial in guaranteeing the steady integration, expression, and inheritance of transgenes. In addition, the study examines numerous crucial case studies where molecular farming has been effectively employed. These activities encompass the creation of antigens for vaccines targeting infectious illnesses such as influenza and HPV, as well as the manufacturing of monoclonal antibodies for the treatment of autoimmune disorders and malignancies. The conversation encompasses the process of bringing these drugs generated from plants into the commercial market. It explores the case of Elelyso, a treatment that replaces enzymes and is manufactured from carrot cells, which has successfully entered the market. Although molecular farming offers promise benefits, it faces several scientific and regulatory obstacles. Significant obstacles include the variation in protein expression levels across various plant hosts, challenges in extracting and purifying the proteins, and the requirement for substantial clinical studies to prove both safety and effectiveness. Furthermore, the regulations governing plant-derived medicines are intricate and strict, frequently necessitating tailored frameworks to accommodate the distinct characteristics of plant-based manufacturing systems. The report finishes by evaluating the future potential of molecular farming in relation to the changing requirements of the pharmaceutical business. The technology's intrinsic adaptability and capacity

for expansion make it especially beneficial for quickly addressing health emergencies, such as pandemics, where conventional manufacturing methods may not be able to fulfill the immediate need for drugs. The ongoing progress in plant biotechnology, vector engineering, and regulatory science is expected to broaden the therapeutic uses of molecular farming, solidifying its role as a crucial component of cutting-edge drug production methods.
Keywords- Molecular farming, plant derived pharmaceuticals.

Introduction

Molecular farming, or pharming, is a biotechnological method that uses plants as bioreactors to manufacture valuable medicines, vaccines, and therapeutic proteins (1). This novel approach has several benefits compared to standard pharmaceutical manufacturing methods, such as cost efficiency, scalability, and the capability to synthesise intricate proteins that are difficult to create using old techniques (2). The fundamental principle of molecular farming is genetically modifying plants to produce specific medicinal proteins by introducing foreign genes (3). Transgenic plants are grown in controlled environments, such as fields, greenhouses, or growth chambers, where they produce medicinal proteins through biosynthesis in their tissues (4). After the harvest, the desired protein is isolated, processed, and prepared for use in medicinal applications.

A key benefit of molecular farming is its cost-efficiency. Plant-based production systems exhibit reduced capital and operating expenses in comparison to conventional fermentation-based techniques (5). In addition, plants provide a versatile and adjustable platform for production, hence decreasing the requirement for specialised infrastructure (6).

Molecular farming has the additional benefit of scalability. Plants may be cultivated on a significant magnitude, facilitating the manufacturing of medications in enough numbers to satisfy worldwide demand (7). The capacity to scale up production makes molecular farming well-suited for manufacturing vaccines and other biologics that are needed in huge volumes (8). In addition, plants have the innate capacity to carry out intricate post-translational changes, such as glycosylation, that play a vital role in the biological function of several therapeutic proteins (9). Plants possess the potential to synthesise complex proteins that are difficult to manufacture using alternative methods, making them an appealing option for this purpose (10).

The primary objective of molecular farming research is to optimise plant expression systems in order to improve protein production and quality (11). This encompasses the creation of innovative plant promoters, signal peptides, and fusion partners with the aim of enhancing the stability, solubility, and secretion of proteins (12). In addition, scientists are investigating the use of temporary expression methods, such as viral vectors or Agrobacterium-mediated transient expression, to accomplish swift and substantial protein synthesis (13). An area of study within molecular farming is the creation of vaccinations that may be consumed as food (14). Edible vaccines are created by the genetic modification of plants to produce antigens derived from diseases. Upon ingestion, these plants elicit an immunological response, therefore offering defence against the infection (15). Edible vaccines possess the capacity to fundamentally transform immunisation approaches, especially in underdeveloped nations where availability of conventional

vaccinations is restricted (16). Another field of study is the synthesis of therapeutic proteins to combat illnesses including cancer, diabetes, and autoimmune disorders (17). Researchers are now exploring the use of plants as a means to generate monoclonal antibodies, which are employed in the treatment of cancer and several other illnesses (18). Ultimately, molecular farming is a very promising biotechnological strategy that presents a multitude of benefits compared to conventional techniques of pharmaceutical manufacturing (19). Further investigation and advancement in this domain are anticipated to result in novel and groundbreaking treatments for various illnesses, while also enhancing the availability of vital medications in developing nations (20).

Principles of Molecular Farming

A. Genetic Engineering of Plants for Pharmaceutical Protein Production

1. Gene Insertion Techniques

Genetic engineering in molecular farming utilises accurate gene insertion techniques to include foreign genes that encode medicinal proteins into the genetic makeup of plants. The Agrobacterium-mediated transformation technique is commonly used because of its high efficiency and capability to precisely insert genes at particular locations. This method entails genetically modifying Agrobacterium tumefaciens, a bacterium found in soil, to include the required gene onto its Ti plasmid. Subsequently, the genetically altered Agrobacterium is employed to invade plant tissues, therefore introducing the gene into the plant genome (21). This approach is preferred due of its capacity to accomplish consistent transformation and precise gene integration. Another method for inserting genes is biolistic or particle bombardment, when DNA-coated particles are delivered into plant cells using a gene cannon. Although biolistic transformation is not as accurate as Agrobacterium-mediated transformation in terms of gene insertion position, it is a flexible method that enables the transformation of a diverse array of plant species.

2. Selection of Host Plants

In molecular farming, the selection of a host plant is crucial and is determined by several parameters, such as transformation efficiency, growth characteristics, biomass output, and protein expression levels. Tobacco (Nicotiana tabacum), maize (Zea mays), and potato (Solanum tuberosum) are frequently used as host plants because they are easily modified genetically and have established procedures for doing so (22). Moreover, these plants exhibit substantial biomass generation and may thrive in many habitats. The choice of the host plant is also contingent upon the preferred protein expression mechanism. Chloroplast transformation is the ideal method for achieving high-level expression of certain proteins due to the ability of the chloroplast genome to produce substantial quantities of protein (23). In contrast, nuclear transformation may be more suited for proteins that need precise post-translational modifications or intricate folding procedures. Additionally, the selection of a host plant may be impacted by the requirement for glycosylation or other post-translational modifications that are necessary for the biological function of the medicinal protein. Plants possess inherent mechanisms to carry out these alterations, rendering them appealing hosts for synthesising complex proteins. Genetic engineering is essential in molecular farming since it allows for the synthesis of medicinal proteins in plants (24). The field of gene insertion methods and host plant selection is constantly advancing,

leading to advancements in the manufacture of valuable medicines and biologics.

B. Plant-Based Production Systems

1. Growth Conditions and Cultivation Methods

The effectiveness of molecular farming depends on the ideal growing conditions and cultivation techniques used for the host plants. Temperature, light intensity, humidity, and food availability are important elements that significantly impact plant growth and productivity in pharmaceutical protein manufacturing. Controlled environment agriculture (CEA) systems, including as hydroponics, aeroponics, and vertical farming, provide meticulous regulation of environmental variables. These techniques facilitate cultivation throughout the year, enhance the production of biomass, and maintain stable levels of protein expression (25). CEA systems may be customised to accommodate the distinct needs of many plant species, guaranteeing ideal growing conditions for the highest possible protein yield.

Although CEA provides notable benefits, conventional field growing techniques are still employed for large-scale molecular farming. Nevertheless, field farming is very vulnerable to variations in the environment, infestations by pests, and outbreaks of diseases, all of which can have a significant influence on both plant growth and protein expression levels. In order to reduce these dangers, farmers may employ pesticides and herbicides. However, it is crucial to exercise caution to prevent any negative impact of these chemicals on the safety or quality of the medicinal proteins meant for human consumption.

2. Harvesting and Extraction Processes

The process of harvesting and extracting plays a crucial role in molecular farming, since it has a direct influence on the quantity and quality of the therapeutic protein. The timing of harvest is critical, as it directly impacts the protein amount and composition in plant tissues (26). Optimal protein output and quality may be achieved by employing unique harvesting methods tailored to different plant species and plant sections.

Following the harvest, the plant material is subjected to extraction in order to separate and isolate the medicinal protein. Multiple extraction techniques are utilised, such as mechanical procedures (such as grinding or pressing), chemical methods (such as solvent extraction), and biological methods (such as enzymatic extraction). The selection of the extraction technique is contingent upon variables such as the characteristics of the protein, the desired level of purity, and the necessary quantity of output. After the extraction process, the protein is subjected to purification in order to eliminate contaminants and get a product that is highly pure. Common purification procedures encompass chromatography, filtration, and precipitation processes, among other others (27). The selection of these techniques is dependent on the protein's features, including its size, charge, and solubility. To summarise, plant-based production systems for molecular farming need careful control of growing conditions and culture techniques to maximise protein output. Efficient harvesting and extraction methods are crucial for producing pharmaceutical proteins of superior quality that are acceptable for medicinal use. Technological and scientific advancements are continuously improving these processes, which are leading to the creation of cutting-edge plant-based pharmaceutical production systems.

C. Post-translational Modifications in Plants

1. Significance of Protein Functionality

Post-translational modifications (PTMs) are crucial for ensuring the correct configuration, operation, and control of proteins. Plants, similar to other living beings, employ various post-translational modifications (PTMs) to alter proteins after their synthesis. Glycosylation is a prevalent post-translational modification (PTM) in plants, including the addition of sugar molecules to proteins. Glycosylation has the potential to influence the stability, solubility, and activity of proteins. Within the realm of plants, intricate glycosylation processes can result in the synthesis of proteins that possess a wide range of glycan structures (28). These structures have the potential to impact the protein's functionality and its ability to interact with other molecules. Phosphorylation is another significant post-translational modification (PTM) in plants, including the addition of phosphate groups to proteins. Phosphorylation is vital for controlling protein activity, location, and interaction with other molecules. Proteins that play a role in signalling networks, gene expression, and stress responses are frequently subjected to phosphorylation, which underscores the significance of this post-translational modification in plant biology. In addition, acetylation, methylation, and proteolytic cleavage are examples of additional post-translational modifications (PTMs) that can impact the functioning of proteins in plants. These alterations have the potential to modify the stability, activity, and location of proteins, and play a role in regulating several cellular processes.

2. Impact on Therapeutic Protein Production

Plants' capacity to carry out intricate post-translational modifications (PTMs) makes them appealing candidates for generating therapeutic proteins. Several pharmaceutical proteins need certain post-translational modifications (PTMs) to achieve appropriate folding, stability, and functionality (29). Plants have a distinct advantage in this aspect, since they are capable of carrying out post-translational modifications (PTMs) that are challenging to do in other systems of expression. For instance, when glycoproteins are synthesised in plants, they can create complex N-linked glycans that closely resemble those found in humans, as opposed to the glycans produced in other expression systems. This can decrease the likelihood of an immune response to the protein and enhance its effectiveness and safety in therapeutic uses. In addition, it is possible to genetically modify plants to create proteins that have certain post-translational modifications (PTMs), which might improve their medicinal characteristics. For instance, the incorporation of certain glycans might enhance the pharmacokinetics of a protein or direct it towards specific tissues or cell types inside the body.

Ultimately, post-translational alterations are crucial in determining the functioning and effectiveness of medicinal proteins that are manufactured in plants. Plants' capacity to carry out intricate post-translational modifications (PTMs) renders them excellent hosts for the production of therapeutic proteins with improved characteristics (30). Further investigation in this field shows significant potential for the creation of innovative medications derived from plants, resulting in enhanced therapeutic effects.

1. Plant Expression Systems in Molecular Farming

A. Promoters and Enhancer

1. Role in Gene Expression

Promoters and enhancers are essential regulatory elements in plant gene expression systems that control the transcription of genes that encode medicinal proteins. Promoters are specific regions of DNA

positioned upstream of a gene that function as binding sites for RNA polymerase and other transcription factors, therefore starting the process of transcription. Enhancers are regulatory elements that can amplify the activity of a promoter, resulting in higher amounts of gene expression (31). When it comes to molecular farming, choosing the right promoters and enhancers is crucial in order to achieve optimal amounts of pharmaceutical protein synthesis. Plant molecular farming often relies on powerful constitutive promoters, such as the cauliflower mosaic virus 35S promoter (CaMV35S), since they can effectively induce high levels of gene expression in a diverse array of plant tissues and under different environmental circumstances (32). These promoters provide strong and uniform expression of the desired gene, which is crucial for optimising protein production.

Alternatively, tissue-specific promoters can be used to limit the production of the medicinal protein to certain plant tissues or organs. This strategy offers benefits in terms of directing protein synthesis to certain tissues where it is most required or reducing the risk of unintended impacts on other areas of the plant.

2. Optimization Strategies

Efficient optimisation of promoter and enhancer elements is crucial for maximising gene expression levels in plant molecular farming. An approach entails altering promoter sequences to augment their activity or specificity. Synthetic promoters can be created by merging components from other promoters to produce a more powerful or tissue-specific promoter. Enhancers can also be employed to enhance the levels of gene expression. Researchers can boost the transcriptional activity of a promoter and increase gene expression by adding enhancer elements either before or after the promoter (33). In addition, the use of transcriptional activator proteins might augment gene expression by selectively binding to certain DNA regions and enlisting the transcription machinery to the promoter. In plant molecular farming, the optimisation of promoters and enhancers is essential for attaining elevated levels of medicinal protein synthesis. Researchers can optimise the manufacturing process for optimum yield and efficiency by selectively choosing and changing regulatory components to suit the unique needs of their target protein.

B. Signal Peptides and Fusion Partners

1. Enhancement of Protein Stability and Secretion

Signal peptides are essential for guiding proteins to their appropriate subcellular compartments and promoting their release from cells. Signal peptides are employed in molecular farming to direct medicinal proteins towards secretion into the extracellular space, facilitating their easy extraction and purification. Moreover, signal peptides have the capacity to augment the stability of proteins by providing protection against cellular breakdown. Fusion partners are employed as a technique to enhance both the stability and secretion of proteins in molecular farming. To augment the total production and release of the target protein, scientists can combine it with a stabilising partner, such as a carrier protein or a protein with high secretion efficiency. Fusion partners can enhance the purification of the target protein by introducing extra purification tags or by enhancing the protein's solubility.

2. Instances of Effective Implementations

An exemplary instance of the effective use of signal peptides and fusion partners in molecular farming is the manufacturing of genetically engineered antibodies in plants. Antibodies are complex proteins that need accurate folding and post-translational

changes to ensure optimal functionality. Researchers have successfully established elevated levels of antibody production and release in plants by combining the antibody with a signal peptide obtained from plants and a stabilising fusion partner. Another instance involves the synthesis of medicinal enzymes, such as alpha-1 antitrypsin, within plants. Alpha-1 antitrypsin is a vital protein that safeguards the lungs against harm caused by enzymes generated during inflammation (34). Researchers have effectively synthesised therapeutic alpha-1 antitrypsin protein in plants at levels appropriate for medicinal use by using signal peptides and fusion partners to improve stability and secretion. Moreover, signal peptides and fusion partners have been utilised in the synthesis of vaccination antigens in plants. Researchers have increased the stability and release of vaccination antigens by optimising the signal peptides and fusion partners. This has resulted in enhanced immune responses in animal models. Signal peptides and fusion partners are essential tools in molecular farming since they enhance the stability and production of medicinal proteins. Further study in this field is anticipated to enhance the synthesis of valuable therapeutic proteins in plants, with potential uses in medicine, agriculture, and biotechnology.

C. Transient Expression Systems

1. Advantages over Stable Transformation

Transient expression techniques provide several benefits compared to steady transformation approaches in molecular farming. One major benefit is the rapidity with which proteins may be synthesised. Transient expression enables the expedited synthesis of proteins within a timeframe of days to weeks, in contrast to the extended period of months needed for stable transformation. The quick time it takes to complete this process is especially beneficial for generating proteins required for time-sensitive medicinal treatments or research endeavours. Scalability is another benefit of temporary expression. Transient expression systems may be readily adjusted in size to achieve the necessary quantities of protein synthesis. The capacity to scale up or down makes transient expression a perfect method for manufacturing proteins in varying amounts, ranging from tiny research batches to large-scale industrial production.

Transient expression has the advantage of being able to choose from a wide range of host plants. Unlike permanent transformation, which necessitates the creation and analysis of transgenic plant lines, transient expression may be accomplished in several plant species and tissues without the requirement for considerable genetic alteration (35). The versatility of this approach enables researchers to rapidly evaluate various plant expression systems in order to enhance protein output.
In addition, temporary expression systems can be utilised to generate proteins that may provide challenges or be unfeasible to manufacture utilising stable transformation approaches. Transient expression can be advantageous for producing proteins that are harmful to the host plant or need extensive post-translational modifications.

2. Current Developments and Future Potential

The present research in transient expression systems is concentrated on enhancing efficiency, scalability, and protein quality. An area of study involves the creation of new viral vectors for temporary expression. These vectors have the ability to transport genes that encode medicinal proteins with more efficiency compared to conventional approaches, resulting in increased production of proteins. Another field of study is optimising plant growth conditions and transformation techniques to improve

transient expression. Through the process of fine-tuning these parameters, researchers have the ability to optimise protein production levels and enhance the uniformity and excellence of the proteins that are generated.

The future potential of transient expression systems resides in their ability to create intricate proteins, such as monoclonal antibodies and vaccine antigens (36). Transient expression provides a cost-efficient and scalable approach for generating these proteins, which are highly sought after for medicinal and scientific applications. Moreover, temporary expression systems can be employed to quickly address emergent infectious illnesses or bioterrorism concerns. Transient expression systems possess the capability to significantly transform our approach to addressing worldwide health emergencies by rapidly generating substantial amounts of therapeutic proteins. Transient expression systems have several benefits over stable transformation approaches in molecular farming, making them a preferable choice. Continual study and improvement of these systems show significant potential for producing valuable pharmaceutical proteins in plants, which might be used in medicine, agriculture, and biotechnology.

2. Applications of Molecular Farming

A. Production of Vaccines

1. Advantages over Traditional Vaccine Production

Molecular farming offers several benefits compared to conventional approaches for vaccine manufacturing, especially in terms of scalability, safety, and delivery techniques. Plant-based solutions offer a significant benefit in terms of scalability. Plants may be grown in huge quantities in a very short time, allowing for quick vaccine manufacture in response to disease outbreaks or rising demand (37). The scalability of plant-based systems makes them more cost-effective compared to traditional approaches that depend on costly bioreactors and cell culture equipment.

Molecular farming for vaccine manufacturing offers a notable benefit in terms of safety. Plant-based solutions eliminate the need for pathogenic organisms or animal-derived products, hence minimising the danger of contamination with pathogens or adventitious agents. Due to their intrinsic safety profile, plant-derived vaccinations are more appropriate for use in both humans and animals.Moreover, plant-based technologies have the capability to administer vaccines orally. Oral administration of some vaccines produced from plants eliminates the requirement for injections, hence increasing convenience and accessibility of immunisation, particularly in settings with low resources. Oral vaccinations further elicit immune responses in the mucosal tissues, which are crucial for defending against infections that invade the body via mucosal surfaces.

2. Instances of Vaccines Derived from Plants

Multiple vaccines derived from plants have been created and examined for different contagious illnesses. An exemplary instance is the development of a vaccine targeting the hepatitis B virus (HBV) using genetically modified tobacco plants. The HBV surface antigen (HBsAg) was effectively produced in tobacco plants and demonstrated to induce a defensive immunological response in animal experiments. An further illustration is the creation of a vaccine for Norwalk virus, a prevalent source of viral gastroenteritis, using genetically modified potatoes. The capsid protein of the Norwalk virus was produced in potatoes and shown to elicit an immunological response in animal models. Moreover, plant-based methods have been

employed to manufacture vaccines targeting influenza virus, human papillomavirus (HPV), and several other pathogenic pathogens (38). Plant-based vaccines provide potential for enhancing worldwide vaccination availability and alleviating the impact of infectious illnesses.

To summarise, molecular farming has several benefits for vaccine manufacturing, such as the capacity to easily increase output, ensuring safety, and the possibility of administering vaccines orally. Plant-based vaccines have demonstrated potential in treating many infectious illnesses and have the capacity to enhance global health outcomes. Further research and development in this sector are anticipated to boost the usability and efficacy of plant-based vaccine manufacturing.

B. Production of Therapeutic Proteins

1. Overview of Therapeutic Proteins Produced in Plants

Plants are now recognised as important bioreactors for the production of a wide range of therapeutic proteins, such as antibodies, enzymes, hormones, and vaccines. A significant achievement in plant-based manufacturing is the creation of monoclonal antibodies (mAbs). These monoclonal antibodies play a crucial role in the treatment of a wide range of ailments including cancer, autoimmune disorders, and infectious diseases (39). Plants have various benefits for producing monoclonal antibodies (mAbs), such as being cost-effective, easily scalable, and capable of performing intricate post-translational changes that are essential for mAb performance. In addition to monoclonal antibodies (mAbs), plants have played a crucial role in the production of therapeutic enzymes used in the treatment of illnesses. Glucocerebrosidase, which is employed for the treatment of Gaucher's disease, and alpha-1 antitrypsin, which plays a vital role in emphysema therapy, are synthesised in plants at appropriate amounts for therapeutic purposes. These plant-produced proteins have demonstrated encouraging outcomes in clinical studies.
Plants are also employed for synthesising hormones such as insulin and growth factors, which play a crucial role in the management of diabetes and growth problems. Insulin that is generated by plants has shown to be biologically active, significantly decreasing levels of glucose in the blood in animal models.

2. Clinical Applications and Effectiveness

Therapeutic proteins generated by plants have demonstrated considerable potential in clinical studies for a range of disorders. An example of this is a monoclonal antibody (mAb) against the Ebola virus that is generated by plants. This mAb has shown effectiveness in experiments conducted before clinical trials, and it is presently being tested in clinical trials for the treatment of Ebola virus infection. Likewise, a monoclonal antibody (mAb) generated by plants has demonstrated effectiveness in preclinical research and is currently undergoing evaluation in clinical trials for the treatment of respiratory syncytial virus (RSV) infection. Enzymes derived from plants have also exhibited efficacy in clinical studies. Glucocerebrosidase generated by plants has demonstrated enhanced symptom relief and decelerated the advancement of the disease in individuals with Gaucher's disease (40). Alpha-1 antitrypsin generated by plants has demonstrated enhanced pulmonary function and reduced exacerbations in individuals with emphysema.
Plant-produced therapeutic proteins have clinical potential in several other domains. Plant-derived vaccines have demonstrated potential in clinical studies for illnesses like HIV, malaria, and influenza. These vaccines utilise the benefits of plant-based manufacturing, including cost-effectiveness,

scalability, and the capacity to generate robust immune responses. To summarise, plant-based production techniques provide a potential opportunity for manufacturing therapeutic proteins with substantial clinical uses. Due to their cost-effectiveness, scalability, and capacity to carry out intricate post-translational changes, they are highly helpful in the advancement of new therapeutics. Further advancements in research and development in this sector are expected to boost the usefulness and efficiency of plant-based manufacturing systems for therapeutic proteins.

C. Edible Vaccines

1. Concept and Development

Edible vaccines are a novel method of immunisation, where the antigenic protein of a disease is produced in plants that may be consumed. The approach, initially introduced in the 1990s, seeks to address the obstacles related to conventional methods of vaccination administration and dissemination. Edible vaccinations have several benefits, such as convenient delivery, less dependence on skilled medical staff, and enhanced durability during storage and transit. Edible vaccines are created by genetically modifying plants to produce particular antigens from a desired disease. Subsequently, these antigens are ingested, so triggering the immune system to generate a defensive immunological response (41). Several plant species, including tomatoes, bananas, potatoes, and tobacco, have been used to create edible vaccinations. In order to guarantee safety and effectiveness, edible vaccines undergo thorough testing, which includes assessing the amounts of antigen expression, stability, and immunogenicity. Edible vaccines have exhibited favourable outcomes in clinical studies, indicating that they can elicit immunological responses that are equivalent to those of conventional injectable vaccinations.

2. Potential Impact on Global Vaccination Programs

Edible vaccines possess the capacity to revolutionise worldwide immunisation initiatives, especially in areas with limited resources. An important benefit of edible vaccines is their simplicity in terms of delivery. They can be ingested orally, obviating the necessity for injections and skilled medical professionals. This enhances the accessibility of immunisation for distant and underprivileged people, who may have limited access to healthcare services. Moreover, edible vaccines have enhanced durability, which is essential in underdeveloped nations with restricted cold chain infrastructure. The inherent stability of vaccines facilitates their storage and distribution, hence minimising the likelihood of vaccine deterioration and loss. Edible vaccines have the notable benefit of being able to stimulate immune responses in the mucosal tissues. Various infections invade the body via mucosal surfaces, including the respiratory, gastrointestinal, and urogenital tracts (42). Edible vaccines have the ability to activate mucosal immunity, which offers an extra level of defence against certain infections. Introducing edible vaccines has the potential to enhance immunisation rates and alleviate the global burden of infectious illnesses. Ongoing research and development in this area are crucial to fully harness the promise of edible vaccines and include them into worldwide immunisation initiatives.

5. Challenges and Future Directions

A. Regulatory Challenges

1. Safety and Efficacy Considerations

The regulatory difficulty of molecular farming lies in guaranteeing the safety and effectiveness of plant-derived medications. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA),

mandate thorough safety and effectiveness data as a prerequisite for authorising plant-derived medications for human use. Safety issues involve the possibility of unforeseen consequences resulting from genetic alterations, such as the development of allergies or the presence of harmful substances. In order to address these issues, researchers carry out thorough safety evaluations, which involve conducting tests to determine allergenicity and toxicity, in order to guarantee the safety of plant-derived medications for human consumption.Efficacy concerns involve the demonstration of the effectiveness of plant-derived medications in treating the specific condition. Therefore, it is essential to conduct thorough preclinical and clinical investigations in order to ascertain the therapeutic advantages of the medication and identify the most effective dose and method of administration.

2. Approval Processes and Regulations

The process of approving medications produced from plants is complex and differs based on the regulatory authority. In the United States, the FDA applies the same regulations to plant-derived medications as it does to other biologics. This means that considerable preclinical and clinical data is required to substantiate claims of safety and effectiveness. Plant-derived medications in the European Union are regulated by the European Medicines Agency (EMA), which has created rules for their development and approval. In the European Union, the approval procedure also necessitates comprehensive safety and efficacy data, as well as adherence to Good Manufacturing Practice (GMP) requirements.

A significant obstacle in the licencing process of plant-derived medications is the absence of precise regulatory rules designed specifically for these items. Due to its recent emergence, molecular farming does not have established regulatory channels, resulting in uncertainty and delays throughout the licencing process. Furthermore, the worldwide regulatory framework for medications produced from plants is changing, since different nations and regions are implementing diverse regulatory strategies. It is crucial to align these regulatory frameworks and create explicit standards in order to facilitate the global development and approval of medications derived from plants. Ultimately, the research and registration of plant-derived medications face substantial obstacles due to regulatory issues. To tackle these problems, it is crucial for researchers, regulatory authorities, and industry partners to work closely together. Their collaboration is necessary to develop precise rules and guarantee the safety and effectiveness of these groundbreaking products.

B. Intellectual Property Rights

1. Ownership of Genetically Modified Plants

Establishing ownership rights of genetically modified (GM) plants is a crucial obstacle in the field of molecular farming. Genetically modified (GM) plants are created by inserting genes from other organisms, which raises questions about the ownership of the intellectual property (IP) rights to these changed plants and their resulting products. Usually, the firm or institution that develops the GM plant has the intellectual property rights to both the plant and its output. These rights are usually protected by patents, which grant exclusive rights to use, sell, and licence the innovation for a specific period of time. However, determining ownership may be complex, especially when numerous parties are participating in the creation process.

Ownership conflicts may occur when partnerships or joint ventures contribute to the creation of genetically modified (GM)

plants. In such instances, it is crucial to have agreements that clearly define the ownership of intellectual property and the allocation of royalties. These agreements are necessary to prevent conflicts and provide a fair and equal distribution of profits.

2. Patent Issues and Licensing Agreements

Patents play a crucial role in safeguarding the intellectual property rights of genetically modified plants and their products. Patent holders are given exclusive rights to economically exploit their innovation and prohibit unauthorised usage by others. Obtaining patents for genetically modified (GM) plants can be challenging because of the complex characteristics of plant genetics and the lengthy and expensive process of applying for a patent.

Licencing agreements are frequently used to oversee the intellectual property rights linked to genetically modified plants. These agreements allow patent holders to authorise others to utilise, sell, or licence the patented innovation in return for royalties or other types of remuneration. These agreements are crucial in enabling the commercialization of genetically modified plants and their products by allowing other companies to access and use the technology. However, the process of dealing with patent concerns and licencing agreements can be difficult in the field of molecular farming. Detractors contend that patents on genetically modified (GM) plants and their products have the potential to hinder scientific research and innovation by restricting access to crucial genetic resources. Moreover, conflicts about intellectual property rights might result in legal complications and hinder the progress and commercialization of genetically modified plants. To summarise, successful management of intellectual property rights in molecular farming requires careful examination of ownership concerns, patent difficulties, and licencing arrangements. It is crucial to employ collaborative methods that consider the concerns of all parties involved in order to guarantee ethical and fair development and commercialization of GM plants and their products.

C. Future Prospects and Developments

1. Emerging Technologies and Trends

The field of molecular farming is now undergoing significant technological developments and emerging trends that have the potential to completely transform the manufacturing of medications derived from plants. Genome editing methods, including CRISPR-Cas9, are being used to accurately change plant genomes, making it one of the most important developing technologies. This method allows researchers to precisely change plant DNA, resulting in the creation of plants with improved characteristics for pharmaceutical manufacture, such as higher protein expression and superior protein quality. One additional developing pattern is the use of transient expression systems for the quick and efficient manufacturing of medicinal proteins. Transient expression systems provide several benefits compared to stable transformation approaches, such as quicker production times and the capability to generate proteins in non-transgenic plants, hence decreasing regulatory obstacles. Scientists are also investigating the use of plant cell suspension cultures and plant-based bioreactors for the mass manufacture of pharmaceutical proteins. This might potentially enhance manufacturing efficiency and scalability.

Moreover, progress in plant biotechnology is facilitating the creation of plant-based production systems capable of synthesising a diverse array of intricate proteins, such as antibodies, enzymes, and vaccines. These platforms are being enhanced to improve the productivity, quality, and effectiveness of

plant-based medicines, hence increasing their competitiveness compared to conventional manufacturing techniques.

2.

. Plant-based vaccines provide a promising answer to worldwide vaccination obstacles due to their ability to be administered orally and their capability to activate mucosal immunity.

In spite of its **Potential for Personalized Medicine and Novel Therapies**

Plant-derived medicines have significant promise for personalised treatment and the creation of innovative therapeutics. Plant-based manufacturing methods may be customised to manufacture precise proteins or vaccinations that are suited to the unique requirements of individual patients. The technique, referred to as "pharming," has the capacity to transform the management of several illnesses, such as cancer, autoimmune disorders, and infectious diseases. Pharmaceuticals generated from plants have the ability to solve medical requirements that have not been satisfied and provide new therapeutic choices for illnesses that have limited therapy alternatives. Plant-based manufacturing methods are now employed to create novel medicines for uncommon diseases, including Gaucher's disease and lysosomal storage disorders, for which conventional therapy choices are restricted. Furthermore, the use of medications generated from plants can effectively tackle worldwide health issues, including the accessibility and cost of vaccines. Plant-derived vaccines and therapies provide a cost-efficient and easily expandable method for manufacturing crucial medications, especially in poor nations with restricted healthcare capabilities.

Ultimately, the outlook for molecular farming is optimistic, since innovative technology and current patterns are propelling progress in plant-based production systems. These advancements have the capacity to completely transform the manufacturing of medications derived from plants and provide a new age of individualised medicine and innovative treatments. Ongoing research and development in this area are crucial to fully exploit the capabilities of plant-based medications and enhance global health results.

1. Conclusion

Molecular farming is a cutting-edge biotechnological discovery that provides a revolutionary method for manufacturing valuable medications derived from plants. This genetic engineering technology allows for the alteration of plants to produce therapeutic proteins, vaccines, and other medications with exceptional efficiency and accuracy. The resultant products provide several benefits, including as cost efficiency, scalability, and the capability to produce intricate proteins with crucial post-translational modifications.

The fundamental concepts of molecular farming are crucial for its success, involving the genetic manipulation of plants, the improvement of plant-based production systems, and the comprehension of post-translational alterations. The development of genome editing and transient expression systems is driving progress and improving the efficiency and adaptability of plant-based manufacturing, leading to the continuous evolution of these features.

Molecular farming has shown great potential in preclinical and clinical environments, especially in the fields of vaccines and therapeutic proteinsexceptional promise, molecular farming has obstacles that need to be resolved in order for it to be widely adopted. Key obstacles include regulatory intricacies, challenges related to intellectual property rights, and the necessity for more

research and development. To successfully address these problems, it is imperative for researchers, regulatory agencies, and industry stakeholders to work closely together in order to guarantee the safety, effectiveness, and availability of medications derived from plants.

Ultimately, molecular farming signifies a pioneering domain in biotechnology and medicine, on the verge of transforming the manufacturing of drugs. To fully exploit the promise of this technology and provide new, groundbreaking drugs derived from plants to the market, it is crucial to continue doing research, fostering innovation, and promoting collaboration. By undertaking this action, we may greatly enhance worldwide health results and propel the area of biotechnology forward for future generations.

References

1. Kamenarova, K., Abumhadi, N., Gecheff, K., & Atanassov, A. (2005). Molecular farming in plants: an approach of agricultural biotechnology. Journal of cell and molecular biology, 4(4), 77-86.
2. Chen, Q., Lai, H., Hurtado, J., Stahnke, J., Leuzinger, K., & Dent, M. (2013). Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins. Advanced techniques in biology & medicine, 1(1).
3. Abiri, R., Valdiani, A., Maziah, M., Shaharuddin, N. A., Sahebi, M., Yusof, Z. N. B., ... & Talei, D. (2016). A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Current Issues in Molecular Biology, 18(1), 21-42.
4. Saveleva, N. V., Burlakovskiy, M. S., Yemelyanov, V. V., & Lutova, L. A. (2016). Transgenic plants as bioreactors to produce substances for medical and veterinary uses. Russian Journal of Genetics: Applied Research, 6, 712-724.
5. Kumar, M., Goyal, Y., Sarkar, A., & Gayen, K. (2012). Comparative economic assessment of ABE fermentation based on cellulosic and non-cellulosic feedstocks. Applied Energy, 93, 193-204.
6. Diego-Martin, B., González, B., Vazquez-Vilar, M., Selma, S., Mateos-Fernández, R., Gianoglio, S., ... & Orzáez, D. (2020). Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoor farms into biomanufacturing facilities. Frontiers in plant science, 11, 612781.
7. Adamo, A., Beingessner, R. L., Behnam, M., Chen, J., Jamison, T. F., Jensen, K. F., ... & Zhang, P. (2016). On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science, 352(6281), 61-67.
8. Zeghibe, A. C. (2021). Growing Into Their Own?: Plant Molecular Farming and the Pursuit of Biotechnological Sovereignty for Lower and Middle Income Countries (Doctoral dissertation, Wellesley College).
9. Pandey, V. K., Sharma, R., Prajapati, G. K., Mohanta, T. K., & Mishra, A. K. (2022). N-glycosylation, a leading role in viral infection and immunity development. Molecular biology reports, 49(8), 8109-8120.
10. Schillberg, S., Raven, N., Spiegel, H., Rasche, S., & Buntru, M. (2019). Critical analysis of the commercial potential of plants for the production of recombinant proteins. Frontiers in plant science, 10, 453222.
11. Schillberg, S., Raven, N., Spiegel, H., Rasche, S., & Buntru, M. (2019). Critical analysis of the commercial potential of plants for the production of recombinant

proteins. Frontiers in plant science, 10, 453222.

12. Sharma, A. K., & Sharma, M. K. (2009). Plants as bioreactors: recent developments and emerging opportunities. Biotechnology advances, 27(6), 811-832.

13. Doyle, C., Higginbottom, K., Swift, T. A., Winfield, M., Bellas, C., Benito-Alifonso, D., ... & Whitney, H. M. (2019). A simple method for spray-on gene editing in planta. BioRxiv, 805036.

14. Ma, J. K. C., Barros, E., Bock, R., Christou, P., Dale, P. J., Dix, P. J., ... & Twyman, R. M. (2005). Molecular farming for new drugs and vaccines: current perspectives on the production of pharmaceuticals in transgenic plants. EMBO reports, 6(7), 593-599.

15. Langridge, W. H. (2000). Edible vaccines. Scientific American, 283(3), 66-71.

16. Roychoudhury, A. (2020). Edible Vaccines and Oral Immunization against Viruses: Prospects, Promises and Pitfalls. SF J Med Res. 2020; 1 (3), 1012.

17. Larche, M., & Wraith, D. C. (2005). Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature medicine, 11(Suppl 4), S69-S76.

18. Halk, E. L., & De Boer, S. H. (1985). Monoclonal antibodies in plant-disease research. Annual Review of Phytopathology, 23(1), 321-350.

19. Schillberg, S., Raven, N., Fischer, R., M Twyman, R., & Schiermeyer, A. (2013). Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Current pharmaceutical design, 19(31), 5531-5542.

20. Saeed, U., Insaf, R. A., Piracha, Z. Z., Tariq, M. N., Sohail, A., Abbasi, U. A., ... & Fazal, I. (2023). Crisis averted: a world united against the menace of multiple drug-resistant superbugs-pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal. Frontiers in Microbiology, 14, 1270018.

21. Gelvin, S. B. (2003). Agrobacterium-mediated plant transformation: the biology behind the "gene-jockeying" tool. Microbiology and molecular biology reviews, 67(1), 16-37.

22. Snow, A. A., Andow, D. A., Gepts, P., Hallerman, E. M., Power, A., Tiedje, J. M., & Wolfenbarger, L. L. (2005). Genetically engineered organisms and the environment: Current status and recommendations 1. Ecological Applications, 15(2), 377-404.

23. Gao, M., Li, Y., Xue, X., Wang, X., & Long, J. (2012). Stable plastid transformation for high-level recombinant protein expression: promises and challenges. BioMed Research International, 2012.

24. Abiri, R., Valdiani, A., Maziah, M., Shaharuddin, N. A., Sahebi, M., Yusof, Z. N. B., ... & Talei, D. (2016). A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Current Issues in Molecular Biology, 18(1), 21-42.

25. Mattsson, L., Sörenson, E., Capo, E., Farnelid, H. M., Hirwa, M., Olofsson, M., ... & Legrand, C. (2021). Functional diversity facilitates stability under environmental changes in an outdoor microalgal cultivation system. Frontiers in Bioengineering and Biotechnology, 9, 651895.

26. Sams, C. E. (1999). Preharvest factors affecting postharvest texture. Postharvest biology and Technology, 15(3), 249-254.

27. Englard, S., & Seifter, S. (1990). [22] Precipitation techniques. In Methods in

enzymology (Vol. 182, pp. 285-300). Academic Press.

28. Lannoo, N., & Van Damme, E. J. (2015). Review/N-glycans: The making of a varied toolbox. Plant Science, 239, 67-83.

29. Walsh, G., & Jefferis, R. (2006). Post-translational modifications in the context of therapeutic proteins. Nature biotechnology, 24(10), 1241-1252.

30. Gomord, V., & Faye, L. (2004). Posttranslational modification of therapeutic proteins in plants. Current opinion in plant biology, 7(2), 171-181.

31. Andersson, R., & Sandelin, A. (2020). Determinants of enhancer and promoter activities of regulatory elements. Nature Reviews Genetics, 21(2), 71-87.

32. Jamil, A., Riaz, S., Ashraf, M., & Foolad, M. R. (2011). Gene expression profiling of plants under salt stress. Critical Reviews in Plant Sciences, 30(5), 435-458.

33. Andersson, R., & Sandelin, A. (2020). Determinants of enhancer and promoter activities of regulatory elements. Nature Reviews Genetics, 21(2), 71-87.

34. Dhami, R. K. (2000). The role of alpha-1-antitrypsin in the development of pulmonary emphysema (Doctoral dissertation, University of British Columbia).

35. Komarova, T. V., Baschieri, S., Donini, M., Marusic, C., Benvenuto, E., & Dorokhov, Y. L. (2010). Transient expression systems for plant-derived biopharmaceuticals. Expert review of vaccines, 9(8), 859-876.

36. Komarova, T. V., Baschieri, S., Donini, M., Marusic, C., Benvenuto, E., & Dorokhov, Y. L. (2010). Transient expression systems for plant-derived biopharmaceuticals. Expert review of vaccines, 9(8), 859-876.

37. Shanmugaraj, B., I. Bulaon, C. J., & Phoolcharoen, W. (2020). Plant molecular farming: A viable platform for recombinant biopharmaceutical production. Plants, 9(7), 842.

38. Venkataraman, S., Hefferon, K., Makhzoum, A., & Abouhaidar, M. (2021). Combating human viral diseases: will plant-based vaccines be the answer?. Vaccines, 9(7), 761.

39. Bosch, X., Saiz, A., Ramos-Casals, M., & BIOGEAS Study Group. (2011). Monoclonal antibody therapy-associated neurological disorders. Nature Reviews Neurology, 7(3), 165-172.

40. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., ... & Berger, M. G. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. International journal of molecular sciences, 18(2), 441.

41. Kaattari, S. L., & Piganelli, J. D. (1996). The specific immune system: humoral defense. In Fish physiology (Vol. 15, pp. 207-254). Academic Press.

42. Williams, A. E. (2011). Immunology: mucosal and body surface defences. John Wiley & Sons.